<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652821</url>
  </required_header>
  <id_info>
    <org_study_id>AAI-US-122</org_study_id>
    <nct_id>NCT00652821</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions</brief_title>
  <official_title>To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AAI Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative bioavailability of Kali and Ortho-McNeil's products&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the relative bioavailability of Kali's Tramadol/APAP 37.5mg/325mg with&#xD;
      Ortho-McNeil's Ultracet tablets 37.5mg/325mg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extent of Absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>To Determine Bioequivalence Under Fed Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Kali product under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Ortho-Mcneil product under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol/ APAP</intervention_name>
    <description>Tablets 37.5mg /325mg</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ultracet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultracet</intervention_name>
    <description>Tablets, 37.5mg/325mg</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Tramadol/APAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Males and females between 18 and 45 years of age inclusive&#xD;
&#xD;
          -  Informed of the nature of the study and given written informed consent.&#xD;
&#xD;
          -  Have a body weight within 15% of the appropriate range as defined in the 1983&#xD;
             Metropolitan Life Company tables and weighing at least 100lbs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to Tramadol/ Acetaminophen, opioids such as morphine and codeine, or&#xD;
             related compounds, or a history or seizures.&#xD;
&#xD;
          -  Any history of a clinical condition which might affect drug absorption, metabolism or&#xD;
             excretion.&#xD;
&#xD;
          -  Recent history (within one year) of mental illness, drug illness, drug abuse or&#xD;
             alcoholism.&#xD;
&#xD;
          -  Donation of greater than 500mL of blood in the past 4 weeks prior to study dosing or&#xD;
             difficulty in donating blood.&#xD;
&#xD;
          -  Received an investigational drug within the 4 weeks prior to study dosing.&#xD;
&#xD;
          -  Currently taking any prescription medication, except oral contraceptives, within 7days&#xD;
             prior to study dosing or over-the-counter medication within 3 days of the study&#xD;
             dosing.&#xD;
&#xD;
          -  This prohibition does not include vitamins or herbal preparations taken as nutritional&#xD;
             supplements for non-therapeutic indications as judged by the physician.&#xD;
&#xD;
          -  Tobacco use(&gt;5 cigarettes per day)in the 3 months prior to study dosing.&#xD;
&#xD;
          -  If female, the subject is lactating or has a positive pregnancy test at screening and&#xD;
             prior to each of the two treatment periods.&#xD;
&#xD;
          -  Females of child bearing potential must use a medically acceptable method of&#xD;
             contraception throughout the entire study period and for one week after the study is&#xD;
             completed.&#xD;
&#xD;
          -  Medically acceptable methods of contraception that may be used by the subject and/or&#xD;
             her partner are:oral contraceptive, progestin injection or implants, condom with&#xD;
             spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical&#xD;
             sterilization of their partner(s) or abstinence.&#xD;
&#xD;
          -  females taking oral contraceptives must have taken them consistently for at least&#xD;
             three months prior to receiving study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Scallion</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAI Clinic</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc</organization>
  </responsible_party>
  <keyword>bioequivalence, single-dose, fed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

